Femke Heindryckx

Summary

Affiliation: Ghent University
Country: Belgium

Publications

  1. ncbi Experimental mouse models for hepatocellular carcinoma research
    Femke Heindryckx
    Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium
    Int J Exp Pathol 90:367-86. 2009
  2. ncbi Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice
    Femke Heindryckx
    Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
    J Hepatol 57:61-8. 2012
  3. ncbi Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model
    Femke Heindryckx
    Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
    Eur J Gastroenterol Hepatol 24:1020-32. 2012
  4. ncbi Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor
    Bram Blomme
    Department of Hepatology and Gastroenterology, Ghent University Hospital, 9000 Ghent, Belgium
    Mol Cell Biochem 372:199-210. 2013
  5. ncbi Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice
    Christophe Van Steenkiste
    Department of Hepatology and Gastroenterology, Ghent University Hospital, Ghent, Belgium
    Hepatology 53:1629-40. 2011
  6. ncbi Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma
    Femke Heindryckx
    Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
    Mol Cancer 9:219. 2010
  7. ncbi Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease
    Stephanie Coulon
    Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
    Cytokine 59:442-9. 2012

Collaborators

Detail Information

Publications7

  1. ncbi Experimental mouse models for hepatocellular carcinoma research
    Femke Heindryckx
    Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium
    Int J Exp Pathol 90:367-86. 2009
    ..Transgenic mice expressing viral genes, oncogenes and/or growth factors allow the identification of pathways involved in hepatocarcinogenesis...
  2. ncbi Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice
    Femke Heindryckx
    Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
    J Hepatol 57:61-8. 2012
    ..The effect of prolyl hydroxylase domain 2 on the pathogenesis of liver cancer has never been studied...
  3. ncbi Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model
    Femke Heindryckx
    Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
    Eur J Gastroenterol Hepatol 24:1020-32. 2012
    ..PlGF is a homologue of the vascular endothelial growth factor, which is only involved in pathological angiogenesis, therefore, its inhibition does not induce adverse effects...
  4. ncbi Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor
    Bram Blomme
    Department of Hepatology and Gastroenterology, Ghent University Hospital, 9000 Ghent, Belgium
    Mol Cell Biochem 372:199-210. 2013
    ..On the protein level, 5D11D4-treatment had a prominent effect on the MAP kinase pathway with a significant p38 activation, yet independent of Ets-1 function...
  5. ncbi Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice
    Christophe Van Steenkiste
    Department of Hepatology and Gastroenterology, Ghent University Hospital, Ghent, Belgium
    Hepatology 53:1629-40. 2011
    ..CONCLUSION: PlGF is a disease-candidate gene in liver cirrhosis, and inhibition of PlGF offers a therapeutic alternative with an attractive safety profile...
  6. ncbi Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma
    Femke Heindryckx
    Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
    Mol Cancer 9:219. 2010
    ..The goal of our study was (1) to develop an efficient mouse model for HCC research, in which tumours develop in a natural background of fibrosis and (2) to assess the time-dependent angiogenic changes in the pathogenesis of HCC...
  7. ncbi Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease
    Stephanie Coulon
    Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
    Cytokine 59:442-9. 2012
    ..These data indicate the involvement of inflammatory (TNFα and IL6), angiogenic (VEGF) cytokines and sVEGFR1 in the pathophysiology of NAFLD...